Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.40 |
| ▸ | ECE1 | P42892 | 7/20 | 0.40 |
| ▸ | GRM5 | P41594 | 4/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392887 | 0.78 | MME (0.40) | MMEECE1GRM5HCAR2CHRM2 | |
| SCHEMBL29493529 | 0.78 | GRM5 (0.42) | MMEECE1GRM5HCAR2CHRM2 | |
| SCHEMBL29745157 | 0.78 | CYP2C19 (0.50) | MMEECE1GRM5HCAR2CHRM2 | |
| SCHEMBL17771436 | 0.78 | GRM5 (0.42) | MMEECE1GRM5HCAR2CHRM2 | |
| SCHEMBL29633563 | 0.78 | MME (0.43) | MMEECE1GRM5HCAR2CHRM2 | |
| SCHEMBL23122854 | 0.78 | CYP2C19 (0.50) | MMEECE1GRM5HCAR2CHRM2 | |
| SCHEMBL2163949 | 0.78 | MME (0.43) | MMEECE1GRM5HCAR2CHRM2 | |
| SCHEMBL29251289 | 0.78 | GRM5 (0.52) | MMEECE1GRM5PTGDR2TRPV3 | |
| SCHEMBL28016125 | 0.77 | GRM5 (0.43) | MMEECE1GRM5HCAR2PTGDR2 | |
| Charcoal, Activated SCHEMBL31286314 | 0.76 | GRM5 (0.50) | MMEECE1GRM5PTGDR2TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986616-B1 | TRICYCLIC TRIAZOLIC COMPOUNDS AS SIGMA RECEPTORS LIGANS | ESTEVE LABOR DR (ES) | 2017-03-29 | — | — | EP | disclosed |
| US-9512142-B2 | Tricyclic triazolic compounds | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-12-06 | — | — | US | disclosed |
| US-20160060275-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-03-03 | — | — | US | disclosed |
| EP-2986616-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS AS SIGMA RECEPTORS LIGANS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-02-24 | — | — | EP | disclosed |
| WO-2014170494-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS AS SIGMA RECEPTORS LIGANS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-10-23 | — | — | WO | disclosed |
| EP-2792679-A1 | Tricyclic triazolic compounds | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-10-22 | — | — | EP | disclosed |
| US-8362011-B2 | Tricyclic triazolic compounds | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-01-29 | — | — | US | disclosed |
| US-8362011-B2 | Tricyclic triazolic compounds | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-01-29 | — | — | US | disclosed |
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| EP-2227476-B1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE LABOR DR (ES) | 2011-09-07 | — | — | EP | disclosed |
| US-20100298309-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-11-25 | — | — | US | disclosed |
| EP-2227476-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-09-15 | — | — | EP | disclosed |
| EP-2070933-A1 | Tricyclic triazolic compounds | Laboratorios del Dr. Esteve S.A. (ES) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070933-A1 | Tricyclic triazolic compounds | Laboratorios del Dr. Esteve S.A. (ES) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009071657-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071657-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-11 | — | — | WO | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| EP-0749430-B1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS | AMERICAN HOME PROD (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5605918-A | SUBSTITUTED THIAZOLIDINE-2,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| US-5574051-A | HYPOGLYCEMIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | MME 2448/4885ECE1 2187/4885GRM5 1/4885 |
| US-20100298309-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | SIGMAR1, OPRK1, OPRM1 | MME 2706/4885ECE1 1921/4885GRM5 330/4885 |
| US-20160060275-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | SIGMAR1, OPRK1, OPRM1 | MME 2501/4885ECE1 2739/4885GRM5 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.